Advertisement
Advertisement
U.S. Markets open in 7 hrs 34 mins
Advertisement
Advertisement
Advertisement
Advertisement

Adagio Therapeutics, Inc. (ADGI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.09+0.35 (+5.19%)
At close: 04:00PM EST
7.13 +0.04 (+0.56%)
After hours: 07:55PM EST
Advertisement

Adagio Therapeutics, Inc.

303 Wyman Street
Suite 300
Waltham, MA 02451
United States
603-252-2274
https://adagiotx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Rene Russo BCPS, Pharm.DCo-Founder & Independent Chair of the Board78.34kN/A1975
Dr. Tillman Ulf Gerngross Ph.D.Co-Founder, CEO, Pres & DirectorN/AN/A1964
Dr. Rebecca Dabora Ph.D.Chief Technology & Manufacturing Officer622.28kN/A1959
Ms. Lynn Connolly M.D., Ph.D.Chief Medical Officer430.89kN/A1967
Ms. Laura Walker Ph.D.Co-Founder & Chief Scientific OfficerN/AN/A1985
Ms. Jane Pritchett V. HendersonCFO & TreasurerN/AN/A1966
Mr. David Hering M.B.A.Chief Operating OfficerN/AN/A1975
Ms. Jill Andersen J.D.Chief Legal OfficerN/AN/AN/A
Dr. Elham Hershberger Pharm.D.Chief Devel. OfficerN/AN/A1968
Mr. Eric W. Kimble M.B.A.Chief Commercial OfficerN/AN/A1967
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. Its lead product candidate is the ADG20, a neutralizing antibody that is in Phase II/III clinical trials for the treatment and prevention of coronavirus disease. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. Adagio Therapeutics, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

Corporate Governance

Adagio Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement